How does albumin influence paclitaxel's membrane penetration?

Short answer: albumin helps paclitaxel reach and enter tumors by using natural albumin transport pathways, improving its delivery across the endothelial barrier and into tumor tissue, where paclitaxel is then released inside cancer cells.

Key points:

- Solubility and formulation: paclitaxel is very hydrophobic. When bound to albumin (as in nab-paclitaxel), it becomes more soluble in blood and can be formulated without Cremophor, reducing formulation-related issues and stabilizing systemic exposure.

- Endothelial transcytosis (crossing the blood vessel barrier): albumin can bind to the gp60 receptor on endothelial cells and trigger caveolae-mediated transcytosis. This “albumin shuttle” helps paclitaxel travel across the vascular endothelium into the tumor interstitium, increasing local drug delivery to tumors.

- Tumor retention and uptake: many tumors overexpress SPARC (also known as osteonectin), which binds albumin. This can lead to greater accumulation and retention of albumin-bound paclitaxel inside the tumor microenvironment, enhancing overall penetration and exposure of cancer cells to the drug.

- Cellular uptake and release: once inside the tumor tissue, paclitaxel dissociates from albumin and diffuses into cancer cells, where it binds tubulin and exerts its cytotoxic effect.

- Pharmacokinetics and safety: albumin-bound formulations often show different pharmacokinetics (e.g., longer circulation time, altered tissue distribution) and can reduce some solvent-related toxicities associated with conventional solvent-based paclitaxel.

In summary, albumin acts as a carrier that (1) increases solubility, (2) promotes transendothelial transport via gp60/caveolae, (3) enhances tumor accumulation via SPARC-mediated interactions, and (4) releases paclitaxel inside tumor cells to achieve effective membrane/permeation and cytotoxic effects.